Home / Pharmaceuticals / Peptide Therapeutics Market By Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Phase Peptide Synthesis (HPPS)), By Delivery Route (Oral Route, Parenteral Route, Pulmonary Route, Mucosal Route), By Applications (Cancer, Cardiovascular Diseases, Metabolic Diseases, Central Nervous System, Infectious Diseases, Gastrointestinal Diseases, Renal Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

Peptide Therapeutics Market By Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Phase Peptide Synthesis (HPPS)), By Delivery Route (Oral Route, Parenteral Route, Pulmonary Route, Mucosal Route), By Applications (Cancer, Cardiovascular Diseases, Metabolic Diseases, Central Nervous System, Infectious Diseases, Gastrointestinal Diseases, Renal Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

Published: Feb 2017 | Report Code: 58361-02-17

This report on global peptide therapeutics market studies various type of application, delivery route, technology and geography. The advantages of using peptide-based molecules for treatment comprises low toxicity, excellent target specificity, high potency, good tolerance, and low incidence of side-effects. The disadvantages of peptide therapeutics are associated with their lack of oral bioavailability due to poor absorption across membrane, imposing parenteral injection as the normal mode of administration which leads to patient inconvenience and discomfort, and to non-compliance. In case competitive scenario of peptide therapeutics market, small biotech companies have seemed to be focusing on a single product or technology, while big pharmaceutical companies possess a diverse portfolio based on therapeutic areas and stresses on collaborations, mergers and acquisitions (M&A), and licensing.

For the purpose of this study, the various types of applications considered are cancer, cardiovascular diseases, metabolic diseases, central nervous system disorders, respiratory diseases, infectious diseases, gastrointestinal diseases, renal disorders, and others (pain management, dermatological disorders, and hematological disorders). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The market segmentation on the basis types of delivery route comprises sub-segments such as oral route, parenteral route, pulmonary route, mucosal route, and other routes (intradermal & nasal). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The market segmentation on the basis types of technology includes sub-segments such as solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid phase peptide synthesis (HPPS). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The geographic segmentation of the global peptide therapeutics market includes regions such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.

The key players covered in peptide therapeutics market are Amgen Inc., Amylin Pharmaceuticals LLC (Bristol- Myers Squibb), AstraZeneca plc, Bachem Holding AG, Eli Lilly and Company, GlaxoSmithKline plc, Ipsen, Lonza, Inc., Merck & Co., Novartis AG, Novo- Nordisk A/S, Peptisyntha, PolyPeptide Group, Pfizer, Inc., F. Hoffman-La Roche AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Peptide Therapeutics Market, by Technology Type, 2015 v/s 2024 (Value %)
2.2 Global Peptide Therapeutics Market, by Delivery Route Type, 2015 v/s 2024 (Value %)
2.3 Global Peptide Therapeutics Market, by Application Type, 2015 (USD Mn)
2.4 Global Peptide Therapeutics Market, by Geography, 2015 (Value %)

Chapter 3 Global Peptide Therapeutics Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence of cancer is boosting the need for research and development in Peptide Therapeutics
3.2.2 Incessant growth in research and development coupled with technological advances in field of therapeutic treatment
3.3 Market Restraints
3.3.1 Complex manufacturing techniques are increasing intricacy for API manufacturers in peptide therapeutics industry
3.4 Market Opportunities
3.4.1 Along with expected drug approvals in peptide therapeutics market the upcoming patent cliff for drugs available in existing market
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Peptide Therapeutics, by Key Players

Chapter 4 Global Peptide Therapeutics Market Analysis, By Technology Type
4.1 Overview
4.2 Solid Phase Peptide Synthesis (SPPS)
4.3 Liquid Phase Peptide Synthesis (LPPS)
4.4 Hybrid Phase Peptide Synthesis (HPPS)

Chapter 5 Global Peptide Therapeutics Market Analysis, By Delivery Route
5.1 Overview
5.2 Oral Route
5.3 Parenteral Route
5.4 Pulmonary Route
5.5 Mucosal Route
5.6 Other Routes (Intradermal & Nasal)

Chapter 6 Global Peptide Therapeutics Market Analysis, By Applications
6.1 Overview
6.2 Cancer
6.3 Cardiovascular Diseases
6.4 Metabolic Diseases
6.5 Central Nervous System
6.6 Infectious Diseases
6.7 Gastrointestinal Diseases
6.8 Renal Disorders
6.9 Others(Pain Management, Dermatological Disorders, and Hematological Disorders)

Chapter 7 Global Peptide Therapeutics Market, By Geography
7.1 Preface
7.2 North America (U.S. & Canada)
7.3 Europe (U.K, Germany, and Rest of the Europe)
7.4 Asia-Pacific (China, Japan, and Rest of Asia-Pacific)
7.5 Latin America (Brazil, Mexico, and Rest of LATAM)
7.6 Middle East and Africa

Chapter 8 Company Profiles
8.1 Amgen Inc.
8.2 Amylin Pharmaceuticals LLC (Bristol- Myers Squibb)
8.3 AstraZeneca plc
8.4 Bachem Holding AG
8.5 Eli Lilly and Company
8.6 GlaxoSmithKline plc
8.7 Ipsen
8.8 Lonza, Inc.
8.9 Merck & Co.
8.10 Novartis AG
8.11 Novo- Nordisk A/S
8.12 Peptisyntha
8.13 PolyPeptide Group
8.14 Pfizer, Inc.
8.15 F. Hoffman-La Roche AG
8.16 Sanofi S.A.
8.17 Takeda Pharmaceutical Company Limited
8.18 Teva Pharmaceuticals

List Of Table :

TABLE 1 Market Competition Assessment: Peptide Therapeutics , by Key Players
TABLE 2 Global Peptide Therapeutics Market, by Technology Type, 2014-2023 (USD Mn)
TABLE 3 Global Peptide Therapeutics Market, by Delivery Route, 2014-2024 (USD Mn)
TABLE 4 Global Peptide Therapeutics Market, by Applications, 2014-2024 (USD Mn)
TABLE 5 Global Peptide Therapeutics Market, by Geography, 2014 – 2024 (USD Mn)
TABLE 6 Amgen Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Amylin Pharmaceuticals LLC (Bristol- Myers Squibb): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 AstraZeneca plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Bachem Holding AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Eli Lilly and Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 11 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 12 Ipsen: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 Lonza, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Merck & Co.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 16 Novo- Nordisk A/S: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 17 Peptisyntha: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 18 PolyPeptide Group: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 19 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 20 F. Hoffman-La Roche AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 21 Sanofi S.A.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 22 Takeda Pharmaceutical Company Limited: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 23 Teva Pharmaceuticals: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Figure :

FIG. 1 Peptide Therapeutics Market: Research Methodology
FIG. 2 Global Peptide Therapeutics Market, by Technology Type, 2015 v/s 2024 (Value %)
FIG. 3 Global Peptide Therapeutics Market, by Delivery Route Type, 2015 v/s 2024 (Value %)
FIG. 4 Global Peptide Therapeutics Market, by Application Type, 2015 (USD Mn)
FIG. 5 Global Peptide Therapeutics Market, by Geography, 2015 (Value %)
FIG. 6 Attractive Investment Proposition, by Geography, 2015
FIG. 7 Global Solid Phase Peptide Synthesis (SPPS) Technology Market in Peptide Therapeutics, 2014 – 2024 (USD Mn)
FIG. 8 Global Liquid Phase Peptide Synthesis (LPPS) Market in Peptide Therapeutics, 2014 – 2024 (USD Mn)
FIG. 9 Global Hybrid Phase Peptide Synthesis (HPPS) Market in Peptide Therapeutics, 2014 – 2024 (USD Mn)
FIG. 10 Global Oral Route Drug Delivery Market in Peptide Therapeutics, 2014 – 2024 (USD Mn)
FIG. 11 Global Parenteral Route Drug Delivery Market in Peptide Therapeutics, 2014 – 2024 (USD Mn)
FIG. 12 Global Pulmonary Route Drug Delivery Market in Peptide Therapeutics, 2014 – 2024 (USD Mn)
FIG. 13 Global Mucosal Route Drug Delivery Market in Peptide Therapeutics, 2014 – 2024 (USD Mn)
FIG. 14 Global Other Routes Drug Delivery Market in Peptide Therapeutics, 2014 – 2024 (USD Mn)
FIG. 15 Global Peptide Therapeutics Application Market in Cancer Treatment, 2014 – 2024 (USD Mn)
FIG. 16 Global Peptide Therapeutics Application Market in Cardiovascular Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 17 Global Peptide Therapeutics Application Market in Metabolic Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 18 Peptide Therapeutics Application Market in Central Nervous System Disorder Treatment, 2014 – 2024 (USD Mn)
FIG. 19 Peptide Therapeutics Application Market in Respiratory Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 20 Peptide Therapeutics Application Market in Infectious Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 21 Peptide Therapeutics Application Market in Gastrointestinal Diseases Treatment, 2014 – 2024 (USD Mn)
FIG. 22 Peptide Therapeutics Application Market in Renal Disorders Treatment, 2014 – 2024 (USD Mn)
FIG. 23 Peptide Therapeutics Application Market in Other Disorders Treatment, 2014 – 2024 (USD Mn)
FIG. 24 North America Peptide Therapeutics Market , 2014 – 2024 (USD Mn)
FIG. 25 Europe Peptide Therapeutics Market , 2014 – 2024 (USD Mn)
FIG. 26 Asia-Pacific Peptide Therapeutics Market , 2014 – 2024 (USD Mn)
FIG. 27 Latin America Peptide Therapeutics Market , 2014 – 2024 (USD Mn)
FIG. 28 Middle East and Africa Peptide Therapeutics Market , 2014 – 2024 (USD Mn)

Based on the type of technology, the peptide therapeutics market is segmented into:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Phase Peptide Synthesis (HPPS)

In 2015, solid phase peptide synthesis accounted for the largest market share due to introduction of novel products equipped with SPPS especially focusing on oral route of drug delivery. Some of the examples such as initially Unigene and then Enteris Biopharma developed a technology named Peptelligence which is based on an enteric-coated tablet, whose core formulation contains, in addition to the peptide, an organic acid enzyme inhibitor and a permeation enhancer which is claimed to help penetrate the mucus layer. Merrion Pharmaceuticals is also developing the GIPET technology using an enteric coating to protect the peptide in the acidic gastric medium and ensure peptide release in the small intestine. Thus, several other technologies have been under clinical trials and are expected to enter market in the near future. During the forecast period 2016 – 2024, HPPS was observed as the fastest growing segment due to its increasing adoption in peptide drug manufacturing.

Peptide Therapeutics Market

Peptide market is growing much faster than that of small molecules, and will make up an even larger proportion of the market in the future. Currently there are over 100 approved peptide-based therapeutics on the market, with the majority being smaller than 20 amino acids. Compared with the typical small-molecule drugs that currently make up the majority of the pharmaceutical market, peptides and proteins can be highly selective as they have multiple points of contact with their target. Based on the type of delivery route, the peptide therapeutics market is segmented into:

  • Oral Route
  • Parenteral Route
  • Pulmonary Route
  • Mucosal Route
  • Other Routes (Intradermal & Nasal)

These peptide and protein therapeutics have disadvantages as well, such as low bioavailability and metabolic liability. Oral bioavailability of peptides is limited by degradation in the gastrointestinal (GI) tract as well as their inability to cross the epithelial barrier. These therapeutics tend to have high molecular weights, low lipophilicity and charged functional groups that hamper their absorption. Thus, routes which were of minor importance as parts of drug delivery in the past have assumed added importance in protein and delivery and these include nasal, ophthalmic, buccal, rectal, intrauterine, vaginal, transdermal and pulmonary routes. The oral, nasal and pulmonary route have been the primary non-invasive routes of protein delivery investigated to research in this field to despite the observation that bioavailability of the peptide and proteins have been proven to be very low in most of the non-invasive routes tested. The research & development experts from this field suggested that peptides and proteins are swiftly metabolized in the GI tract, and the hydrophilic nature of most natural peptides constrains movement across the epithelial barrier. Developments in the oral delivery of proteins and peptides have been made by the use of absorption enhancers, enzyme inhibitors and direct structural modification of the therapeutic.

Peptide Therapeutics Market

Based on the type of applications, the peptide therapeutics market is segmented into:

  • Cancer
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Central nervous System Disorders
  • Respiratory Diseases
  • Infectious Diseases
  • Gastrointestinal Diseases
  • Renal Disorders
  • Others (Pain Management, Dermatological Disorders, and Hematological Disorders)

In 2015, cancer segment accounted of the major market share due to rising prevalence of cancers coupled with high disease diagnosis rate, rising public awareness associated with the peptide therapeutics and developing overall healthcare infrastructure and supportive government policies. It was also observed that, naturally occurring peptides are most of the times not directly suitable for its application as convenient therapeutics due to factors such as intrinsic weaknesses, a short circulating plasma half-life, and poor chemical and physical stability. The key disease areas presently driving the therapeutic applications of peptide drugs are oncology and metabolic diseases. The factors aiding epidemic growth of metabolic diseases are both obesity and T2DM, in case of oncology by rising mortality and need for chemotherapy replacement along with cancer supportive care. The application of peptide therapeutics in the treatment of diabetes and obesity is possibly the reason behind largest share of North America in the global peptide drug market, with the Asia-Pacific reflecting the largest growth. However, a current trend observed recently was shifted focus of companies towards the infectious diseases and inflammation or pain management, where several peptides are undergoing clinical testing.

Peptide Therapeutics Market

For the purpose of this study, the global peptide therapeutics market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Peptide Therapeutics Market

North America was observed as the largest market in peptide therapeutics industry due to factors such as high awareness associated with therapeutic treatment developments in public, high acceptance for novel products and technologies from patients and medical practitioners, and high healthcare costs. The European peptide therapeutics market has also projected noticeable growth due to factors such as increasing research and development activities associated with peptide therapeutics, and major merger and acquisitions were observed in Europe peptide therapeutics industry. In addition, the major factor that has fueled the research and development activity in Europe peptide therapeutics industry are rising obesity cases and high prevalence of cardiovascular disorders. In Asia-Pacific excluding Japan other countries are at a nascent stage as compared to the more mature markets of North America and Europe. However, countries such as China, Australia and New Zealand are anticipated to be the largest markets for peptide therapeutics and collectively accounted for 78.4% revenue share in year 2015 of the total Asia-Pacific market (except Japan).

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients